Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.67 |
| ▸ | CES2 | O00748 | 1/20 | 0.67 |
| ▸ | CES1 | P23141 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 2/20 | 0.62 |
| ▸ | BCHE | P06276 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1363813 | 0.88 | CA1 (0.67) | CA1CA2CES2CES1ACHE | |
| SCHEMBL9316829 | 0.85 | CES2 (0.68) | CA1CA2CES2CES1ACHE | |
| SCHEMBL1363815 | 0.85 | CA1 (0.73) | CA1CA2CES2CES1ACHE | |
| SCHEMBL35319 | 0.83 | CA1 (0.71) | CA1CA2CES2CES1ACHE | |
| SCHEMBL25931268 | 0.83 | ALDH1A1 (0.65) | CA1CA2CES2CES1ACHE | |
| SCHEMBL14095660 | 0.82 | ALDH1A1 (0.69) | CA1CA2CES2CES1ACHE | |
| SCHEMBL3930562 | 0.82 | ALDH1A1 (0.69) | CA1CA2CES2CES1ACHE | |
| SCHEMBL18214676 | 0.82 | CA1 (0.59) | CA1CA2CES2CES1ACHE | |
| P-Nitrophenylphosphate SCHEMBL168768 | 0.82 | CA1 (0.69) | CA1CA2CES2CES1ACHE | |
| Dimethyl 4-Nitrophenyl Phosphate SCHEMBL901276 | 0.81 | CA1 (0.68) | CA1CA2CES2CES1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| EP-3856164-B1 | MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS | ACHILLION PHARMACEUTICALS INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-11807627-B2 | Morphic forms of complement factor D inhibitors | Achillon Pharmaceuticals, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220233673-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2022-07-28 | — | — | US | disclosed |
| EP-3980057-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | Institut Curie (FR) | 2022-04-13 | — | — | EP | disclosed |
| US-20210332026-A1 | MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-10-28 | — | — | US | disclosed |
| EP-3856164-A1 | MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS | Achillion Pharmaceuticals, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| CN-112996497-A | Morphic forms of complement factor D inhibitors | 艾其林医药公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2020245321-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020069024-A1 | MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| US-9227937-B2 | Phenoxyalkyl pyridinium oxime therapeutics for treatment of organophosphate poisoning | MISSISSIPPI STATE UNIVERSITY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20130172393-A1 | PHENOXYALKYL PYRIDINIUM OXIME THERAPEUTICS FOR TREATMENT OF ORGANOPHOSPHATE POISONING | MISSISSIPPI STATE UNIVERSITY | 2013-07-04 | — | — | US | disclosed |
| US-20110071334-A1 | FOAMING DECONTAMINATING AQUEOUS SOLUTION | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2011-03-24 | — | — | US | disclosed |
| EP-1732938-B1 | ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-05-06 | — | — | EP | disclosed |
| US-7491710-B2 | Organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2009-02-17 | — | — | US | disclosed |
| EP-1732938-A1 | ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005058923-A1 | ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2005-06-30 | — | — | WO | disclosed |
| US-20050137171-A1 | Novel organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172393-A1 | PHENOXYALKYL PYRIDINIUM OXIME THERAPEUTICS FOR TREATMENT OF ORGANOPHOSPHATE POISONING | PNPO, PLPBP, PDXK | CA1 3257/4885CA2 367/4885CES2 219/4885 |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | CA1 4068/4885CA2 4557/4885CES2 4876/4885 |
| US-11807627-B2 | Morphic forms of complement factor D inhibitors | CFD, CFH, CFB | CA1 4405/4885CA2 4111/4885CES2 4867/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | CA1 3497/4885CA2 4336/4885CES2 4879/4885 |
| US-20050137171-A1 | Novel organophosphorus derivatives of indazoles and use thereof as medicinal products | PPIP5K2, INPPL1, IP6K3 | CA1 2945/4885CA2 1802/4885CES2 133/4885 |
| US-20210332026-A1 | MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | CA1 4405/4885CA2 4111/4885CES2 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.